Patents Examined by Quang Nguyen
  • Patent number: 9700587
    Abstract: Methods for delivering a therapeutic agent to a cerebral cortex or to the cerebral cortex and spinal cord include administering a viral vector that includes the therapeutic agent into white matter of a brain in order to deliver the therapeutic agent to the cerebral cortex or to the cerebral cortex and spinal cord. Kits for performing such methods may include at least one viral vector, at least one therapeutic agent, and a convection enhanced delivery (CED) catheter.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: July 11, 2017
    Assignee: RENISHAW PLC
    Inventors: Steven Streatfield Gill, Neil Barua
  • Patent number: 9694037
    Abstract: Bioimplants and methods of making the bioimplants are provided. The bioimplants comprise biological tissues having conjugated thereto adjunct molecules. The biological tissues are sterilized with a chemical sterilizing agent, such as a water soluble carbodiimide. The processes of making the bioimplants include a process in which an adjunct molecule is conjugated to a biological tissue during the sterilization process.
    Type: Grant
    Filed: January 6, 2009
    Date of Patent: July 4, 2017
    Assignee: Synovis Orthopedic and Woundcare, Inc.
    Inventors: Chandrasekaran Nataraj, Gregg Ritter, Thomas Sander
  • Patent number: 9675662
    Abstract: Compositions for inhibition of RNA Polymerase I include peptides of Rpa43. Methods of production and use thereof are also disclosed.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: June 13, 2017
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Lawrence Rothblum
  • Patent number: 9675642
    Abstract: This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: June 13, 2017
    Assignees: University Of Pittsburgh—Of The Commonwealth System Of Higher Education, Intrexon Corporation
    Inventors: J. Mark Braughler, Prasanna Kumar, Walter J Storkus, Hideho Okada
  • Patent number: 9663790
    Abstract: The present invention is directed to constructs, compositions and methods for modulating platelet-type 12 lipoxygenase (12-LO) in adipose tissue in vivo. Specifically, the invention provides constructs encoding expression-inhibiting oligonucleic acids, e.g. antisense and RNA interfering (RNAi) molecules, targeted to a platelet-type 12-LO gene or a transcript thereof, which are capable of reducing or silencing platelet-type 12-LO expression specifically in adipocytes and pre-adipocytes. Vectors comprising these constructs (including, but not limited to, viral vectors), compositions comprising them and methods of using same for the treatment and amelioration of conditions associated with excess fat cell mass and obesity are also provided.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: May 30, 2017
    Assignee: The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center
    Inventors: Gary Weisinger, Rona Limor, Naftali Stern
  • Patent number: 9657282
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: May 23, 2017
    Assignee: FACTOR BIOSCIENCE, INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 9636388
    Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: May 2, 2017
    Assignee: MORPHOGENESIS, INC.
    Inventors: Michael J. P. Lawman, Patricia D. Lawman, Meghan Gentilini, Vijay Ramiya, Marina Victor Abdelmaseeh Bastawrous
  • Patent number: 9637747
    Abstract: Eukaryotic protein-coding messenger RNAs and non-coding microRNAs are naturally transcribed by type II RNA polymerases (pol-2) but not prokaryotic RNA polymerases. As a result, current eukaryotic RNA and protein production is performed either using eukaryotic pol-2 promoters in hybridomas or mammalian cells or using prokaryotic promoters in bacterial cells. However, because prokaryotic RNA transcription tends to be error-prone, frequent mutation is a big problem. Also, growing hybridomas or mammalian cells is relatively laborious and costly. To overcome these problems, the present invention provides a novel inducible composition and method for producing eukaryotic RNAs and/or their related peptides/proteins directly using eukaryotic pol-2 promoter-driven gene expression in fast growing bacteria, without the need of changing to prokaryotic promoters or growing hybridomas/mammalian cells.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: May 2, 2017
    Assignee: MELLO BIOTECHNOLOGY, INC.
    Inventors: Shi-Lung Lin, Donald C. Chang
  • Patent number: 9572838
    Abstract: A method for production of anti-tumor TRAIL includes inserting a TRAIL molecule, encoded by a viral vector irreversibly derived from a cell line, into a carrier cell, thereby obtaining a stably TRAIL-producing carrier cell, and wherein the TRAIL molecule includes a soluble molecule.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: February 21, 2017
    Inventors: Massimo Dominici, Rita Bussolari, Giulia Grisendi, Pierfranco Conte
  • Patent number: 9527904
    Abstract: Disclosed herein are compositions, systems and methods for delivery of proteins of interest using adeno-associated virus (AAV) vectors.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: December 27, 2016
    Assignee: California Institute of Technology
    Inventors: Alejandro Benjamin Balazs, David Baltimore
  • Patent number: 9517251
    Abstract: The present disclosure provides method of generating cardiomyocytes from post-natal fibroblasts. The present disclosure further provides cells and compositions for use in generating cardiomyocytes.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: December 13, 2016
    Assignee: The J. David Gladstone Institutes
    Inventors: Deepak Srivastava, Masaki Ieda
  • Patent number: 9517250
    Abstract: The present disclosure provides method of generating cardiomyocytes from post-natal fibroblasts. The present disclosure further provides cells and compositions for use in generating cardiomyocytes.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: December 13, 2016
    Assignee: The J. David Gladstone Institutes
    Inventors: Deepak Srivastava, Masaki Ieda
  • Patent number: 9487787
    Abstract: Methods and compositions for the rapid and reversible destabilizing of specific proteins using cell-permeable, synthetic molecules are described. Stability-affecting proteins, e.g., derived from FKBP and DHFR proteins are fused to a protein of interest and the presence or absence of the ligand is used to modulate the stability of the fusion protein.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: November 8, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Thomas J. Wandless, Laura Anne Banaszynski, Mari Iwamoto, Lystranne Alysia Maynard, Ling-Chun Chen
  • Patent number: 9487768
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: November 8, 2016
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 9481867
    Abstract: A method of rapidly inducing large-scale and high-purity mesenchymal stem cells to transdetermine into hematopoietic stem cells is provided with the steps of preparing homogeneous medium of mesenchymal stem cells; combining a plurality of small RNA molecules; assembling and transfecting nanoparticles of nucleic acids and polypeptides; inducing and amplifying medium of post-transdetermined hematopoietic stem cells; and activating a plurality of hemopoiesis-related genes.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: November 1, 2016
    Assignee: BEIJING GINKO BIOSCIENCE CO., LTD.
    Inventor: Qinwei Yin
  • Patent number: 9464285
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: October 11, 2016
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 9458208
    Abstract: Stimulation of target cells using light, e.g., in vivo or in vitro, is implemented using a variety of methods and devices. One example involves a vector for delivering a light-activated molecule comprising a nucleic acid sequence that codes for light-activated molecule. The light-activated molecule includes a modification to a location near the all-trans retinal Schiff base, e.g., to extends the duration time of the open state. Other aspects and embodiments are directed to systems, methods, kits, compositions of matter and molecules for ion channels or pumps or for controlling currents in a cell (e.g., in in vivo and in vitro environments).
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: October 4, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Ofer Yizhar, Lisa Gunaydin, Peter Hegemann, Andre Berndt
  • Patent number: 9447377
    Abstract: The present inventions describes a method that, starting from pluripotent cells, leads to the obtainment, in a reproducible and efficient manner, of endodermal cells precursor. These cells reveal useful also for application in the regenerative therapy.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: September 20, 2016
    Inventors: Stefania Filosa, Genesia Manganelli
  • Patent number: 9447395
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: September 20, 2016
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 9447166
    Abstract: The present invention provides an intraceptor that interacts with and decreases activity of with VEGF and/or a VEGFR for the treatment of angiogenesis-related conditions. The present invention further provides pharmaceutical compositions, and methods of use thereof, for the treatment and prevention of an angiogenesis-related condition using said intraceptors. The invention further provides for nucleic acids encoding said intraceptors.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: September 20, 2016
    Assignees: Medical College of Georgia Research Institute, University of Utah Research Foundation
    Inventors: Balamurali Ambati, Nirbhai Singh, Shivan Amin